Background. The purpose of this study was to determine the influence of clinical characteristics on shock occurrence and survival in 241 patients with implantable cardioverter-defibrillator (ICD) therapy.
VT, ventricular tachycardia. 
Follow-up
Follow-up began at the time of first ICD implantation. End points of follow-up were 1) death from any cause including perioperative mortality, 2) heart transplantation (six patients), 3) last patient visit as of March 1992. All patients were seen routinely every 1-3 months or after device discharge. One hundred ninety-one patients were followed primarily at our hospital. Follow-up evaluation of the remaining 50 patients followed primarily at other centers was completed by telephone communication with the patient and/or the patient's physician and analysis of the response to mailed questionnaires completed by the patient's physician. All spontaneous shocks and deaths during follow-up were classified as defined below. In 20 of the 241 patients (8%), the ICD was removed, inactivated, or not replaced after battery depletion during follow-up for the following reasons: device infection or generator skin erosion (12 patients), refusal of replacement after battery depletion (five patients), end-stage heart failure (two patients), and high defibrillation threshold at attempted generator replacement (one patient). Of note, these 20 patients are included in the survival analysis according to the intention to treat.
Definitions
Perioperative mortality was defined as death from any cause within the first 30 days after ICD implantation or before hospital discharge. Cause of death was defined as previously described by Mosteller et Table 3 . Ejection fraction <30% was the only variable that was independently associated with earlier occurrence of both appropriate and any spontaneous ICD shocks (p=0.001, Figure 3 ). Appropriate and any spontaneous shocks occurred significantly later in patients who presented with a cardiac arrest and in patients in whom only VF but no uniform VT was induced during pre- (p=O.001). nary emboli in two patients, and refractory congestive heart failure with recurrent VT, respiratory failure, and myocardial infarction in one patient each. Including early postoperative mortality, the cause of death during total follow-up was sudden death in 17 patients (7%), arrhythmic/nonsudden death in two patients (1%), cardiac/nonarrhythmic death in 31 patients (13%), and noncardiac death in 23 patients (9%). Actuarial survival data are provided in Table 4 , and Kaplan-Meier curves for survival from sudden death, total cardiac death, and total death are shown in Figure 4 . Of note, the actuarial incidence of death in Table 4 and Figure 4 includes 12 of 20 patients with ICD removal or inactivation for the reasons listed above who died during further follow-up (intention-to-treat analysis). Importantly, four of the 17 patients with sudden death during follow-up died after device inactivation or removal without replacement. Thus, only 13 of 241 patients (5%) experienced sudden death with active ICD during follow-up.
Clinical Characteristics Associated With Arrhythmic Death and Total Mortality
Results of univariate and multivariate Cox analysis of clinical characteristics associated with total arrhythmic and total death are shown in Table 5 . Ejection fraction <30% was the only variable associated with total arrhythmic death (p=0.019) for both univariate and multivariate analysis. Total mortality was also independently associated with an ejection fraction <30% (p=0.003, Figure 5 ). In addition, treatment with type I antiarrhythmic agents but not amiodarone treatment was associated with a higher total mortality (p=0.023) but not with total arrhythmic death. None of the remaining variables including age, sex, underlying heart disease, clinical presentation of the arrhythmia, result of programmed stimulation before ICD implantation, or preceding revascularization was associated with an increase or decrease in arrhythmic or total mortality during follow-up. Of note, the survival curves of patients who received appropriate or any spontaneous shocks were not significantly different from the curves of patients who did not receive shocks (Table 5 ). servations: 1) the actuarial 5-year incidence of appropriate shocks in 63% of patients and of any spontaneous shocks in 76% of patients, 2) the time from the first appropriate or any spontaneous shock to death with a mean of 12 months or 13 months, respectively, with no difference in total arrhythmic and total survival for patients with and without spontaneous shocks, and 3) the low incidence of sudden cardiac death during follow-up in 13 of 241 patients (5%) with active ICD (follow-up, 24+20 months) and 17 of 241 patients (7%) during total follow-up of 26±22 months according to the intention-to-treat analysis. The multivariate analysis of clinical characteristics associated with spontaneous shocks, total arrhythmic death, and total mortality may have important implications for future clinical trials.
Incidence of Spontaneous Shocks
The incidence of appropriate shocks defined as shocks preceded by presyncope or syncope clearly underestimates the true incidence of shocks for ventricular tachyarrhythmias ( Figure 1) . Conversely, the incidence of any spontaneous ICD shocks, excluding shocks for documented non-VT rhythm or device malfunction, clearly overestimates the true incidence of shocks for VT or VF. Therefore, both appropriate and any spontaneous shocks were analyzed in this study. Using this approach, the true incidence of shocks for ventricular tachyarrhythmia recurrence is most likely in the area between the two Kaplan-Meier curves for freedom of appropriate and any spontaneous shocks (Figure 2 ). Of note, the actuarial 5-year incidence of appropriate shocks in 63% of patients in our study is very similar to the findings of other investigators ranging from 62% in the study from Gross and colleagues24 to 69% in the report of Fogoros et a12 and Tchou et al. 25 
Effect of Ejection Fraction on Shock Occurrence and Survival
Poor left ventricular function (ejection fraction <30%) was the only clinical variable in our study that was independently associated with all four dependent variables, i.e., earlier occurrence of appropriate and any spontaneous shocks ( Figure 3 ) and higher total arrhythmic and total mortality (Table 5) . However, the predictive value of preserved left ventricular function at implant for remaining shock free during follow-up is low, since 51% of patients with an ejection fraction >30% are estimated to receive appropriate shocks during 5-year follow-up (Figure 3) . These findings are similar to the results of Levine and colleagues,3 who found an ejection fraction <25% predictive for earlier ICD discharge and shorter survival after ICD discharge. Our results also confirm the finding of Kim and colleagues10 that an ejection fraction <30% is associated with a higher total arrhythmic and total mortality after ICD implant. In our study, patients who died during the early postoperative period after ICD implantation (3%) tended to have a lower ejection fraction of 27±11% as compared with 31±12% in patients who survived the early postoperative period. However, the difference in ejection fraction was not significant because of the small number of patients who died early postoperatively in our study. Similar to our results, a recent multicenter study reported by Mosteller and colleagues6 revealed a significant, inverse correlation between perinotion; patients who died perioperatively had a mean ejection fraction of 26% versus 34% in survivors of ICD implantation.
Effect ofAntiarrhythmic Drug Treatment at the Time of ICD Implantation
Treatment with amiodarone at implantation was independently associated with later occurrence of any spontaneous shocks, but there was no significant difference in the occurrence of appropriate shocks in patients with and without amiodarone at implantation (Table 3) . This finding may merely reflect differences in patient selection for amiodarone therapy at implantation that were not accounted for by the clinical variables listed in Table 3 , such as frequency and hemodynamic tolerance of the clinical VT and intolerance or failure of other antiarrhythmic agents. Treatment with class 1 antiarrhythmic drugs at implantation was associated with a higher total mortality but not with sudden death or total arrhythmic death (Table 5 ). Of note, the lack of increased sudden death or total arrhythmic death rate in patients with class 1 agents at implantation excludes a causal relation between the increased total mortality and potential proarrhythmic effects of class 1 agents. Differences in patient characteristics other than the variables listed in Table 5 '4 age and sex of patients in our study were not independently associated with shock occurrence or survival after ICD implantation (Tables 3 and 5 ). In contrast to the finding of Levine and colleagues3 that coronary bypass surgery at the time of ICD implantation was associated with later occurrence of appropriate ICD shocks, we did not find differences in shock occurrence in patients with and without coronary bypass surgery preceding ICD implantation. This difference may also be due to differences in patient population in both studies. All patients who underwent coronary bypass surgery preceding ICD implantation in our study had a remote myocardial infarction generating the "anatomic substrate" for arrhythmia recurrence, which is unlikely to be altered by revascularization.30 Coronary artery bypass grafting, however, may reduce the role of ischemia for triggering tachyarrhythmias in these patients to a level comparable to patients with a remote myocardial infarction who did not need revascularization, resulting in a similar incidence of shocks during follow-up in both groups in our study.
Limitations of the Study
This study was retrospective and uncontrolled. Similar to all previously published follow-up studies of large patient populations with ICD therapy, electrocardiographic documentation of the rhythm preceding spontaneous ICD shocks was not available in the majority of cases. Shock analysis was, therefore, performed for appropriate and any spontaneous shocks as discussed above. Of note, 67 of 135 patients in our study (50%) who received any spontaneous shocks during follow-up had VT or VF preceding one or more spontaneous shocks documented by Holter or telemetry monitoring or stored electrograms by the device.
Conclusions
The majority of patients receive shocks during longterm follow-up after ICD implantation. The occurrence of appropriate or any spontaneous shocks during follow-up is not associated with increased arrhythmic or total mortality consistent with effective prevention of sudden cardiac death with ICD therapy in this high-risk patient population. Although low ejection fraction is the strongest predictor of both shock occurrence and mortality during follow-up, no easy algorithm can be derived from the analyzed clinical characteristics to predict which patients will benefit most from ICD implantation. The results of this study warrant further investigation and may have important implications for future prospective studies with ICD therapy.
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